Your SlideShare is downloading. ×
Abbott Labs 2012 Presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Abbott Labs 2012 Presentation

240
views

Published on

The Barclays Back To School presentation from Abbott before they split their foods business from the prescription business. @foodsfluidsbynd

The Barclays Back To School presentation from Abbott before they split their foods business from the prescription business. @foodsfluidsbynd

Published in: Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
240
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Barclays Capital HealthCare Conference John LeonardJohn Leonard Senior Vice President, Pharmaceuticals, Research and Development
  • 2. Forward-Looking Statementg Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995,p p g including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertaintiesthat these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive governmental technological and other factors that may affectcompetitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2010 and in the interim reports filed on Form 10-Q for b t t l i d d i t d b f Abb ttsubsequent quarterly periods, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward- looking statements as a result of subsequent events or developments. 2© 2012 Abbott
  • 3. Pharmaceutical Pipeline Snapshot 30 Compounds currently in human trials 15 Biologics currently in pipeline (late Discovery – Phase III) >20 Compounds or indications currently in Phase II or Phase III • Numerous pipeline opportunities with breakthrough potential • Goal to bring to market products that demonstrate: – Strong clinical performance – Patient benefit – Economic value 3© 2012 Abbott
  • 4. R&D Productivityy Enhanced clinical study designs Expanded external validation Better cross- functional input Goal to achieve a success rate significantly higher than industry averagehigher than industry average 4© 2012 Abbott
  • 5. Pharmaceutical Pipeline Highlights Immunologygy Numerous Approaches with Potential for Differentiated Efficacy and Safety DVD-Ig • Proprietary platform enables two antibodies in single agent • Phase I currently underway ABT 122: anti TNF/IL 17 (RA)– ABT-122: anti-TNF/IL-17 (RA) BT-061 (Partner: Biotest) • Novel anti-CD4 antibody; activates T-regulatory cells – Currently in Phase IIa for RA and psoriasisCurrently in Phase IIa for RA and psoriasis GLPG0634 (Partner: Galapagos) • Next-generation, highly selective JAK1 inhibitor • Potential for better safety and efficacy profile vs. other JAK inhibitors in development – Currently in Phase IIa for RA Other Early-Stage Oral Candidates • Evaluating early stage candidates, including: JAK1; SYK, next-generation AIMs 5© 2012 Abbott
  • 6. Pharmaceutical Pipeline Highlights Bardoxolone Bardoxolone: Potential Game-Changer in CKD Treatment Landscape Disease Overview • Current treatments (non-specific) only modestly slow progression • Patients ultimately progress to end-stage disease/dialysis • Significant cost to healthcare systems worldwide Bardoxolone Highlights (Partner: Reata) • Oral, first-in-class anti-inflammatory: Nrf2 activator • Improves kidney’s ability to filter and remove waste from the body (eGFR) • First-and-only treatment shown to reverse disease progression • Phase III program underway, enrolling ahead of forecast – Primary endpoint: time to first event of composite endpoint (ESRD or CV death) • Expect Phase III results in 2013 • Peak Year Opportunity: >$1BN 6© 2012 Abbott pp y
  • 7. Pharmaceutical Pipeline Highlights Daclizumab Daclizumab: Potential for High Efficacy, Manageable Safety in MS Disease Overview • Disorder in which immune system attacks the myelin, which protects nerve fibers • Most common progressive and disabling neurological condition in young adults • $11BN market growing to more than $14BN by 2020 Daclizumab Highlights (Partner: Biogen) • In Phase III development for relapsing remitting MS (RRMS) • Current therapies have either marginal efficacy with nuisance side effects or high efficacy and serious, unpredictable side effects (i.e. PML) • Daclizumab offers potential to deliver right balance of high efficacy, manageable safety • Phase IIb data promising; potential for annual relapse rate similar to other next- generation therapies and possible incremental disability benefit • Phase III results expected in 2014, commercialization 2016 • Peak Year Opportunity: >$1BN 7© 2012 Abbott • Peak Year Opportunity: >$1BN
  • 8. Pharmaceutical Pipeline Highlights HCV Combination HCV Combo: Opportunity for Vast Improvement Over Current Therapies Disease Overview • 180MM people infected worldwide; more than 4MM newly diagnosed per year globally • Heterogeneous disease; number of genotypes and subtypes • $3BN market expected to grow 5-6X by 2019 Abbott Program Highlights • Broad HCV program: Protease, Polymerase and NS5A inhibitors in development • Goal is three-fold: – High cure rates in broadest range of patients – Significantly shorten and simplify course of therapy – Interferon-free • Phase IIb program ongoing, enrolling well; studying various combinations of three MOA • Additional data presented this year will shed further light on our advancing program P k Y O t it $2BN 8© 2012 Abbott • Peak Year Opportunity: >$2BN
  • 9. Pharmaceutical Pipeline Additional Late-Stage Highlightsg g g • Several additional indications in development • Collectively represent ~$1BN peak opportunity HUMIRA Additional Indications Duodopa (LCIG) • Collectively represent ~$1BN peak opportunityIndications • Intestinal gel for advanced Parkinson’s disease • Infused directly into small intestine via portable pump Elagolix Duodopa (LCIG) • Uniquely provides partial estrogen suppression • Currently on market in Europe • U.S. pivotal data and registration submission in 2012 Elagolix (Partner: Neurocrine) • Phase II for uterine fibroids ongoing • On track to start Phase III for endometriosis 1H12 • Currently in Phase III for multiple myelomaElotuzumab Currently in Phase III for multiple myeloma • Phase II results showed high response rates Elotuzumab (Partner: BMY) 9© 2012 Abbott
  • 10. Pharmaceutical Pipeline Summary • Unique and promising pipeline of proprietary pharmaceutical products y p – Highly prevalent conditions – Numerous medicines in development with breakthrough potential P t ti l t d i i ifi t th f th h b d• Potential to drive significant growth for the new research-based pharmaceutical company 10© 2012 Abbott
  • 11. Q&A 11© 2012 Abbott
  • 12. Barclays Capital HealthCare Conference John LeonardJohn Leonard Senior Vice President, Pharmaceuticals, Research and Development